Immune checkpoint inhibitors (ICI): toxicity management
Written and reviewed by Dr Ibrahim Imam, Consultant Neurologist. Last reviewed .
Immune checkpoint inhibitors (ICI): toxicity management. NMDAR, Caspr1, Anti-MOG, Anti-NMO, Paraneoplastic. Fully referenced neurology checklist.
Autoimmune tests
- NMDAR
- Caspr1
- Anti-MOG
- Anti-NMO
- Paraneoplastic
- Anti AChR
- Anti-MUSK
- Anti-ganglioside
- Myositis panel
Other blood tests
Locked: subscribe to see this section.
Other investigations
Locked: subscribe to see this section.
Treatment
Locked: subscribe to see this section.
References
- Spain L, Tippu Z, Larkin JM, Carr A, Turajlic S. How we treat neurological toxicity from immune checkpoint inhibitors. ESMO Open 2019; 4(Suppl 4):e000540.
- Astaras C, de Micheli R, Moura B, Hundsberger T, Hottinger AF. Neurological adverse events associated with immune checkpoint inhibitors: diagnosis and management. Curr Neurol Neurosci Rep 2018; 18:3.
- Thummalapalli R, Sena LA, Probasco JC, Gladstone DE. Checkpoint inhibitor-induced autoimmune encephalitis reversed by rituximab after allogeneic bone marrow transplant in a patient with Hodgkin lymphoma. Leuk Lymphoma 2020; 61:228-230.
